Comparative Pharmacology
Head-to-head clinical analysis: ANTRENYL versus LUSEDRA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ANTRENYL versus LUSEDRA.
ANTRENYL vs LUSEDRA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Antrenyl (oxyphenonium bromide) is a quaternary ammonium anticholinergic agent that competitively blocks acetylcholine at muscarinic receptors in smooth muscle, exocrine glands, and the CNS, leading to reduced gastrointestinal motility and secretion.
LUSEDRA (valbenazine) is a selective vesicular monoamine transporter 2 (VMAT2) inhibitor. It reduces presynaptic dopamine release by inhibiting VMAT2, thereby reducing dopamine neurotransmission in the striatum.
50 mg orally 3 times daily initially, then adjust to 50-100 mg 3 times daily; 20 mg intramuscularly or intravenously every 4-6 hours as needed.
5 mg orally once daily.
None Documented
None Documented
2-4 hours (terminal), requiring q6-8h dosing for sustained anticholinergic effect
8-12 hours (terminal, prolonged in renal impairment; dose adjustment needed if CrCl <30 mL/min).
Renal (80% as unchanged drug and metabolites), biliary/fecal (20%)
Primarily renal (70-80% as unchanged drug); 20-30% via biliary/fecal.
Category C
Category C
Anticholinergic
Anticholinergic